Retension Pharmaceuticals Files 424B4 Prospectus for IPO

Key takeaways

• Retension Pharmaceuticals, Inc. filed a 424B4 final prospectus with the SEC on Oct. 9, 2026, at 5:29 p.m. Eastern time.
• A 424B4 is the document issuers file once an offering has been priced, so the filing marks the move from registration to a completed pricing.
• The EDGAR record lists accession number 0001213900-26-108587 and a filer ID of 2002988. The submission is about 24 MB.
• Readers should go to the prospectus itself for the offer price, share count, underwriters and use of proceeds. This article does not estimate those terms.

What was filed

Retension Pharmaceuticals, Inc. submitted a Rule 424(b)(4) prospectus to the Securities and Exchange Commission late on Friday, Oct. 9, 2026. EDGAR indexes the filing under accession number 0001213900-26-108587. The company’s central index key is 2002988.

The filing is large, about 24 MB. A file that size usually means the full prospectus document plus exhibits or embedded material. For readers, the practical point is that the final terms are in the document itself and not in the index entry.

Why a 424B4 prospectus matters

A 424B4 is not a first look at a deal. A company files an initial registration statement, typically an S-1 for a domestic issuer, and amends it as it responds to SEC comments and markets the offering. The 424B4 comes after the deal is priced. It carries the final numbers that earlier drafts could only show as ranges or blanks.

That makes it the main reference for any IPO pricing review. It fixes the price investors paid in the offering. It also sets out the number of shares sold and the resulting proceeds. The underwriting arrangements and the capitalization table after the offering are in the same document.

The filing date is also a useful marker. A prospectus filed after the close on a Friday normally follows a pricing that took place earlier in the week or the evening before. Trading dates and first-day results can be checked against exchange records and the company’s own announcements.

What to check in the final document

For a pharmaceutical issuer, a few sections tend to matter most when judging a priced IPO:

Section	What it tells you
Cover page and offering summary	Final price, shares offered, any over-allotment option
Use of proceeds	How much goes to clinical work, operations or debt
Dilution and capitalization	What new investors pay compared with existing holders
Risk factors	Regulatory, clinical and financing risks the company flags
Underwriting	Banks involved, fees and lock-up terms

Those items drive the IPO valuation debate. They show what the company raised and how much of the business was sold. They also show how long the cash is expected to last.

Who is affected

Investors who took part in the offering now have the final terms to compare against the marketing range. Existing shareholders should look at the lock-up provisions and the post-offering ownership table. Peers in the pharma and biotech sector will read the pricing as a data point for their own plans to go public.

What to watch next

Several things follow a final prospectus. The first is the opening of trading and the IPO first-day performance, which reflects how the market received the price. The second is the closing of the offering and any exercise of the underwriters’ over-allotment option. The third is the company’s first periodic report as a public issuer. That report starts the quarterly disclosure cycle and shows how the company handles its new reporting duties.

Floto Review will compare the final terms with the earlier registration filings once the full prospectus details are confirmed from the document on EDGAR.